Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Free Report)’s share price dropped 0.7% during mid-day trading on Friday . The stock traded as low as $14.16 and last traded at $14.95. 1,494,645 shares were traded during mid-day trading, an increase of 207% from the average session volume of 486,688 shares. The stock had previously closed at $15.05.
Eliem Therapeutics Trading Down 4.7%
The company has a market cap of $423.97 million, a P/E ratio of -26.89 and a beta of -0.39. The business’s 50 day simple moving average is $14.21 and its 200 day simple moving average is $11.04.
About Eliem Therapeutics
Eliem Therapeutics, Inc is a clinical‐stage biotechnology company focused on the development of novel therapeutics for the treatment of neurological and neuropsychiatric disorders. The company’s scientific approach is centered on proprietary peptide and small‐molecule drug candidates designed to modulate central nervous system pathways. By leveraging targeted delivery and receptor‐specific activity, Eliem seeks to address unmet medical needs in areas such as pain management, spasticity and other debilitating sequelae of spinal cord injury.
The company’s most advanced program, ELI-200, is being investigated as a potential treatment for spasticity and neuropathic pain associated with spinal cord injury.
Further Reading
- Five stocks we like better than Eliem Therapeutics
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
